Rejection prevention

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)

Donor bone marrow infusion did not significantly improve rejection prevention when added to the belatacept-sirolimus regimen, with all three episodes of subclinical rejection occurring in patients who

Effect: null; P=0.22 (Fisher's exact test)